1555 related articles for article (PubMed ID: 17678953)
1. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders.
Lipton SA; Gu Z; Nakamura T
Int Rev Neurobiol; 2007; 82():1-27. PubMed ID: 17678953
[TBL] [Abstract][Full Text] [Related]
2. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
Lipton SA
J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
[TBL] [Abstract][Full Text] [Related]
3. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
Lipton SA
Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105
[TBL] [Abstract][Full Text] [Related]
4. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
Lipton SA
Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
[TBL] [Abstract][Full Text] [Related]
5. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.
Lipton SA
NeuroRx; 2004 Jan; 1(1):101-10. PubMed ID: 15717010
[TBL] [Abstract][Full Text] [Related]
6. Emerging roles of S-nitrosylation in protein misfolding and neurodegenerative diseases.
Nakamura T; Lipton SA
Antioxid Redox Signal; 2008 Jan; 10(1):87-101. PubMed ID: 17961071
[TBL] [Abstract][Full Text] [Related]
7. The chemical biology of clinically tolerated NMDA receptor antagonists.
Chen HS; Lipton SA
J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
[TBL] [Abstract][Full Text] [Related]
8. S-Nitrosylation and uncompetitive/fast off-rate (UFO) drug therapy in neurodegenerative disorders of protein misfolding.
Nakamura T; Lipton SA
Cell Death Differ; 2007 Jul; 14(7):1305-14. PubMed ID: 17431424
[TBL] [Abstract][Full Text] [Related]
9. Redox reactions induced by nitrosative stress mediate protein misfolding and mitochondrial dysfunction in neurodegenerative diseases.
Gu Z; Nakamura T; Lipton SA
Mol Neurobiol; 2010 Jun; 41(2-3):55-72. PubMed ID: 20333559
[TBL] [Abstract][Full Text] [Related]
10. Cell death: protein misfolding and neurodegenerative diseases.
Nakamura T; Lipton SA
Apoptosis; 2009 Apr; 14(4):455-68. PubMed ID: 19130231
[TBL] [Abstract][Full Text] [Related]
11. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
Sonkusare SK; Kaul CL; Ramarao P
Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
[TBL] [Abstract][Full Text] [Related]
12. Redox modulation by S-nitrosylation contributes to protein misfolding, mitochondrial dynamics, and neuronal synaptic damage in neurodegenerative diseases.
Nakamura T; Lipton SA
Cell Death Differ; 2011 Sep; 18(9):1478-86. PubMed ID: 21597461
[TBL] [Abstract][Full Text] [Related]
13. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration.
Uehara T; Nakamura T; Yao D; Shi ZQ; Gu Z; Ma Y; Masliah E; Nomura Y; Lipton SA
Nature; 2006 May; 441(7092):513-7. PubMed ID: 16724068
[TBL] [Abstract][Full Text] [Related]
14. S-nitrosylation of critical protein thiols mediates protein misfolding and mitochondrial dysfunction in neurodegenerative diseases.
Nakamura T; Lipton SA
Antioxid Redox Signal; 2011 Apr; 14(8):1479-92. PubMed ID: 20812868
[TBL] [Abstract][Full Text] [Related]
15. Preventing Ca2+-mediated nitrosative stress in neurodegenerative diseases: possible pharmacological strategies.
Nakamura T; Lipton SA
Cell Calcium; 2010 Feb; 47(2):190-7. PubMed ID: 20060165
[TBL] [Abstract][Full Text] [Related]
16. Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma.
Seki M; Lipton SA
Prog Brain Res; 2008; 173():495-510. PubMed ID: 18929130
[TBL] [Abstract][Full Text] [Related]
17. Aberrant protein S-nitrosylation contributes to the pathophysiology of neurodegenerative diseases.
Nakamura T; Prikhodko OA; Pirie E; Nagar S; Akhtar MW; Oh CK; McKercher SR; Ambasudhan R; Okamoto S; Lipton SA
Neurobiol Dis; 2015 Dec; 84():99-108. PubMed ID: 25796565
[TBL] [Abstract][Full Text] [Related]
18. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond.
Lipton SA
Nat Rev Drug Discov; 2006 Feb; 5(2):160-70. PubMed ID: 16424917
[TBL] [Abstract][Full Text] [Related]
19. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease.
Olivares D; Deshpande VK; Shi Y; Lahiri DK; Greig NH; Rogers JT; Huang X
Curr Alzheimer Res; 2012 Jul; 9(6):746-58. PubMed ID: 21875407
[TBL] [Abstract][Full Text] [Related]
20. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
Rogawski MA; Wenk GL
CNS Drug Rev; 2003; 9(3):275-308. PubMed ID: 14530799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
